Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1007/978-3-030-59261-5_7

http://scihub22266oqcxt.onion/10.1007/978-3-030-59261-5_7
suck pdf from google scholar
33656715!ä!33656715

suck abstract from ncbi

pmid33656715      Adv+Exp+Med+Biol 2021 ; 1321 (ä): 81-96
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Emerging Technologies for the Treatment of COVID-19 #MMPMID33656715
  • Aghamollaei H; Sarvestani R; Bakherad H; Zare H; Guest PC; Ranjbar R; Sahebkar A
  • Adv Exp Med Biol 2021[]; 1321 (ä): 81-96 PMID33656715show ga
  • The new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), turned into a pandemic affecting more than 200 countries. Due to the high rate of transmission and mortality, finding specific and effective treatment options for this infection is currently of urgent importance. Emerging technologies have created a promising platform for developing novel treatment options for various viral diseases such as the SARS-CoV-2 virus. Here, we have described potential novel therapeutic options based on the structure and pathophysiological mechanism of the SARS-CoV-2 virus, as well as the results of previous studies on similar viruses such as SARS and MERS. Many of these approaches can be used for controlling viral infection by reducing the viral damage or by increasing the potency of the host response. Owing to their high sensitivity, specificity, and reproducibility, siRNAs, aptamers, nanobodies, neutralizing antibodies, and different types of peptides can be used for interference with viral replication or for blocking internalization. Receptor agonists and interferon-inducing agents are also potential options to balance and enhance the innate immune response against SARS-CoV-2. Solid evidence on the efficacy and safety of such novel technologies is yet to be established although many well-designed clinical trials are underway to address these issues.
  • |*COVID-19[MESH]
  • |*Coronavirus Infections/drug therapy[MESH]
  • |*Middle East Respiratory Syndrome Coronavirus/genetics[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]
  • |Reproducibility of Results[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box